United States: The First Circuit Agrees that Non-Cash Reverse Payments Are Subject to Antitrust Scrutiny. Does the Loestrin Decision Point to Battles to Come?

Recently, the First Circuit became the second federal appellate court interpreting the Supreme Court's landmark decision in FTC v. Actavis, Inc.[1] to hold that non-cash "reverse payments" between pioneer and generic pharmaceutical manufacturers risk antitrust liability. Like the Third Circuit in King Drug,[2] the First Circuit's decision in In re Loestrin 24 FE Antitrust Litigation held that a pioneer drug manufacturer's agreement not to market an authorized generic product during a generic challenger's 180-day exclusivity period to settle litigation under the Hatch-Waxman Act is subject to rule of reason scrutiny under the Sherman Act.[3]  In reversing the District Court's holding that Actavis does not apply to non-cash reverse payments, Loestrin continues the trend towards expanded liability for settling parties. However, Loestrin's extensive discussion of the pleading standard applicable to Actavis' "large and unjustified payment" factor points toward future battles over the plausibility of complaints alleging non-cash reverse payments.

The dispute in Loestrin centers around Watson Pharmaceuticals, Inc.'s ("Watson") challenge to the validity of Warner Chilcott's ("Warner") patents covering the active ingredient of its drug, Loestrin 24 FE ("Loestrin"), an oral contraceptive, and Watson's plans to market its own generic version of Loestrin. To increase generic pharmaceutical competition, the Hatch-Waxman Act[4] (the "Act") provides generic manufacturers with unique incentives to challenge the patent protection accorded to pioneer drugs. Instead of requiring detailed studies demonstrating efficacy and safety, the Act permits generic challengers to "piggy-back" on the pioneer drug manufacturer's studies using an abbreviated new drug application (an "ANDA") so long as the generic challenger demonstrates bioequivalence.[5]  And, most importantly, the FDA grants the first successful ANDA filer a 180-day exclusivity period during which time other generic challengers are not permitted to market the drug.[6]  The 180-day exclusivity period can be extraordinarily valuable to the generic challenger. However, in order to market a generic drug, a generic challenger must first overcome the pioneer manufacturer's patent monopoly.

The most common form of Hatch-Waxman challenge is known as a Paragraph IV certification. Under Paragraph IV, the generic manufacturer certifies that the pioneer's patents are "invalid or will not be infringed by the manufacture, use, or sale of the [generic] drug."[7]  In almost all cases, a Paragraph IV certification provokes patent infringement litigation by the pioneer manufacturer because certification is an act of constructive infringement and the initiation of litigation triggers a 30-month stay of the FDA's consideration of the ANDA application.[8]

In Loestrin, Watson filed the first ANDA challenging Warner's patent on Loestrin and certified that its generic product did not infringe the patent and/or the patent was invalid under Paragraph IV.[9]  In January 2009, after Warner filed an infringement suit against Watson, the parties entered into a settlement agreement wherein Watson was permitted to market generic Loestrin beginning in January 2014 and Warner agreed not to market an authorized generic Loestrin product during Watson's 180-day exclusivity period.[10]  The agreement also provided fees to Watson for the co-promotion of another drug and rights to sell a third, Warner brand-name drug that was in clinical development.[11]

A group of direct purchasers and end purchasers filed complaints alleging that Warner's agreement not to market an authorized generic during Watson's exclusivity period constituted an illegal reverse payment under Section 1 of the Sherman Act.[12]  Although Actavis had already been decided at the time it reached its decision, in dismissing the purchasers' complaints, the District Court held that non-cash reverse payments, including no authorized generic agreements, are not subject to antitrust scrutiny under Actavis.[13]  The District Court explained: "Reading Actavis, this Court cannot help but find that it applies solely to monetary settlements; the narrowness of the Supreme Court's language and the cash-focused guidance for applying the rule of reason permit no other conclusion until and unless the Supreme Court expands its holding."[14]  In dismissing the complaints, the District Court further relied on Actavis' guidance that a "large and unjustified" payment to the purported generic infringer may serve as a proxy for an agreement to maintain supracompetitive prices and "requires, on the part of the plaintiff, and ultimately the reviewing court (or jury), an ability to assess or calculate the true value of the payment made by the patentee to the generic competitor."[15]  Unlike a cash settlement, the District Court held that "a non-cash settlement, particularly one that is multifaceted and complex...is almost impossible to measure against these [] factors."[16]  Accordingly, the District Court held that Actavis could not be applied to non-monetary settlements and dismissed the plaintiffs' complaints.

Rejecting the District Court's reasoning, the First Circuit held that Actavis applies to non-monetary reverse payments because "the key word used throughout the opinion is 'payment,' which connotes a much broader category of consideration than cash alone."[17]  Notwithstanding, the Loestrin Court agreed that, under Actavis, "the size of the reverse payment, particularly as it relates to potential litigation expenses, is central to the antitrust query and requires that the reviewing court or factfinder [sic] assess the value of the payment."[18]  The Circuit parted ways with the District Court, however, based on Actavis' repeated references to the size of the alleged reverse payment which, in the Circuit Court's view, presupposed that the size of the payment in question – whatever form it takes – is ascertainable.[19]  Accordingly, the First Circuit explained that "[a]lthough the value of non-cash reverse payments may be much more difficult to compute than that of their cash counterparts, antitrust litigation often requires an 'elaborate inquiry into the reasonableness of a challenged business practice' and, as a result, is 'extensive and complex.'"[20]  Stopping short of endorsing a heightening pleading standard, the court held that plaintiffs must "'estimate the value of the term, at least to the extent of determining whether it is large and unjustified.'"[21]  Because the District Court did not assess the size of the alleged reverse payment at issue, the Circuit Court remanded the case for further proceedings.

In addition to expanding reverse payment liability to non-cash reverse payments in the First Circuit, Loestrin confirms that new battle lines are being drawn in reverse payment litigation. Specifically, it appears that plaintiffs' attempts to adequately plead "large and unjustified" non-cash payments will assume greater importance and defendants' challenges to the sufficiency of such pleadings will grow in intensity. Under Iqbal and Twombly, a plaintiff must "state a claim to relief that is plausible on its face" by alleging non-conclusory "factual content that allows the court to draw the reasonable inference that the defendant is liable for the misconduct alleged."[22]  Although Loestrin holds that a plaintiff need only estimate whether the payment is large and unjustified at the pleading stage, the plausibility of such allegations are context-specific, and they must be supported by non-conclusory factual content. On remand and in the cases that follow Loestrin, litigants' ability to meet this standard will be tested.

[1] 133 S. Ct. 2223 (2013).

[2] King Drug Co. of Florence, Inc. v. SmithKline Beecham Corp., 791 F.3d 388 (3d Cir. 2015).

[3] Rochester Drug Co-Operative, Inc. v. Warner Chilcott Co. (In re Loestrin 24 FE Antirust Litig.), 2016 U.S. App. LEXIS 3049, at *28 (1st Cir. Feb. 22, 2016).

[4] 21 U.S.C. § 355, et seq.

[5] 21 U.S.C. § 355(j).

[6] 21 U.S.C. § 355(j)(5)(B)(iii), (iv).

[7] 21 U.S.C. § 355(j)(2)(A)(vii)(IV).

[8] 35 U.S.C. § 271(e)(2)(A); 21 U.S.C. § 355(j)(5)(B)(iii).

[9] Loestrin, 2016 U.S. App. LEXIS 3049, at *15.

[10] Id. at *15-16.

[11] Id. at *16-17.

[12] 15 U.S.C. § 1.

[13] In re Loestrin 24 FE Antitrust Litig., 45 F. Supp. 3d 180, 192 (D.R.I. 2014)).

[14] Id.

[15] Id. at *190.

[16] Id. at *191.

[17] Loestrin, 2016 U.S. App. LEXIS 3049, at *27.

[18] Id. at *30.

[19] Id. at *31.

[20] Id. at *32 (citation omitted).

[21] Id. at *32-33 (quoting In re Actos End Payor Antitrust Litig., 2015 U.S. Dist. LEXIS 127748, at *43, 2015 WL 5610752, at *13) (S.D.N.Y. Sep. 22, 2015). Importantly, the Loestrin Court also held that the five-factor analysis utilized by the Supreme Court in Actavis, which includes "large and unjustified" payments, does "not overhaul the rule of reason, nor should they [sic] create a new five-part framework in antitrust cases."  Loestrin, 2016 U.S. App. LEXIS 3049, at *30 n.12.

[22] Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009); Bell Atlantic Corp. v. Twombly, 550 U.S. 544, 555-56 (2007).

The First Circuit Agrees that Non-Cash Reverse Payments Are Subject to Antitrust Scrutiny. Does the Loestrin Decision Point to Battles to Come?

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.